More room for activities

Accenture to double the size of its Houston innovation hub

Accenture is building out the floor that houses its Houston innovation hub in order to accomodate for its growing client base and staff. Courtesy of Accenture

When Brian Richards, managing director at Accenture, launched the company's Houston innovation hub, he had a team of about a half dozen and 13,500 square feet of space. Now, his crew has surpassed a hundred people, and it's about time the hub's space grows as well.

Accenture is building out the rest of the floor the hub currently resides on. After this process, which is currently ongoing, the hub will be nearly 30,000 square feet.

"Since we've launched, we've been fully booked," Richards tells InnovationMap. "We've had more than 400 workshops with various companies — from both here in Houston and globally."

The first phase of the expansion will allow for Richards and his team to better provide clients — usually large companies — with their services, which is everything from current design thinking to software development services. Construction is expected to be completed later this year.

However, the second phase of this growth project includes the creation of Houston's ICS Cyber Fusion Center to address Accenture clients' growing demand for cybersecurity within industrial capabilities. Currently, the timeline for phase two has not been defined, Richards says.

Accenture's Houston innovation hub hosts its clients with workshops that allow for strategic brainstorming for innovative solutions to problems occurring at the company or within the industry. Most of the hub's clients are within the energy industry. After identifying the problems and coming up with solutions, the hub's team members are able to offer engineering and design services from prototypes to scaling up and implementation, even passing off the client to Accenture's wider scope of services.

"It's a strong recognition of how digital innovation continues to thrive here in Houston and the role Accenture has had in helping develop that ecosystem and supporting it through the innovation hub," Richards says.

Accenture's Houston innovation hub regularly hosts business executives for workshops that allow for hands-on digital technology discovery.Courtesy of Accenture

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News